DMHCA
DMHCA, a potent and selective LXR agonist, specifically activates the cholesterol efflux arm of the LXR pathway without stimulating triglyceride synthesis. DMHCA has anti-inflammatory effects and can be used for the research of cholesterol homeostasis diabetes[1].
Product Specifications
CAS Number
79066-03-8
UNSPSC
12352211
Target
LXR
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor
Applications
Metabolism-sugar/lipid metabolism
Field of Research
Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/dmhca.html
Purity
99.91
Solubility
DMSO : 7.69 mg/mL (ultrasonic)
Smiles
C[C@@]12[C@](CC[C@]2([H])[C@H](C)CCC(N(C)C)=O)([H])[C@@]3([H])[C@@](CC1)([H])[C@@]4(C(C[C@H](CC4)O)=CC3)C
Molecular Formula
C26H43NO2
Molecular Weight
401.63
References & Citations
[1]Cristiano P Vieira, et al. Selective LXR agonist DMHCA corrects retinal and bone marrow dysfunction in type 2 diabetes. JCI Insight. 2020 Jul 9;5 (13) :e137230.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
GTR15220559 1 Vial
Lentiviral mouse Ubb shRNA (UAS) - Lentiviral mouse Ubb shRNA (UAS, RFP) (25)
Sign In for Pricing
View Details 
133423-ML550 100 µL
SLC22A13 (Solute Carrier Family 22 Member 13, Organic Cation Transporter-like 3, OCTL3, ORCTL3, ORCTL-3, OAT10, OCTL1) (MaxLight 550)
Sign In for Pricing
View Details 
GTR15385832 1 Vial
Lentiviral human TMEM200C sgRNA gene knockout kit - Lentiviral human TMEM200C sgRNA gene knockout kit (plasmid)
Sign In for Pricing
View Details